BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21781445)

  • 1. Detection of IDH1 mutations and the status of MGMT promoter on intraoperative fresh tissue section from frameless neuronavigation needle biopsy. Analysis on 17 patients with brain glial tumor ineligible for craniotomy and tumor resection.
    Iaccarino I; Nicoli D; Serra S; Froio E; Pisanello A; De Berti G; Ghadirpour R; Marcello N; Servadei F; Carinci F
    Int J Immunopathol Pharmacol; 2011; 24(2 Suppl):45-50. PubMed ID: 21781445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy of 25 patients with brain tumor.
    Iaccarino C; Nicoli D; Serra S; Froio E; Pisanello A; De Berti G; Ghadirpour R; Marcello N; Servadei F; Carinci F
    Int J Immunopathol Pharmacol; 2011; 24(2 Suppl):37-43. PubMed ID: 21781444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of MGMT promoter methylation status on intraoperative fresh tissue section from frameless neuronavigation needle biopsy: a preliminary study of ten patients.
    Iaccarino C; Nicoli D; Gallo C; Nasi D; Pisanello A; De Berti G; Ghadirpour R; Marcello N; Servadei F
    Acta Neurochir (Wien); 2010 Jul; 152(7):1189-96. PubMed ID: 20354736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of MGMT promoter methylation sites correlating with gene expression and IDH1 mutation in gliomas.
    Zhang J; Yang JH; Quan J; Kang X; Wang HJ; Dai PG
    Tumour Biol; 2016 Oct; 37(10):13571-13579. PubMed ID: 27468718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of molecular markers demonstrates concordance between samples acquired via stereotactic biopsy and open craniotomy in both anaplastic astrocytomas and glioblastomas.
    Gessler F; Baumgarten P; Bernstock JD; Harter P; Lescher S; Senft C; Seifert V; Marquardt G; Weise L
    J Neurooncol; 2017 Jun; 133(2):399-407. PubMed ID: 28508327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation.
    Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M
    Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential Role of Methylation Marker in Glioma Supporting Clinical Decisions.
    Roszkowski K; Furtak J; Zurawski B; Szylberg T; Lewandowska MA
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential influence of IDH1 mutation and MGMT gene promoter methylation on glioma-related preoperative seizures and postoperative seizure control.
    Feyissa AM; Worrell GA; Tatum WO; Chaichana KL; Jentoft ME; Guerrero Cazares H; Ertekin-Taner N; Rosenfeld SS; ReFaey K; Quinones-Hinojosa A
    Seizure; 2019 Jul; 69():283-289. PubMed ID: 31141785
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1/2 Mutation and MGMT Promoter Methylation - the Relevant Survival Predictors in Czech Patients with Brain Gliomas.
    Kramář F; Minárik M; Benešová L; Halková T; Netuka D; Bradáč O; Beneš V
    Folia Biol (Praha); 2016; 62(5):194-202. PubMed ID: 27978414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.
    Mellai M; Piazzi A; Caldera V; Monzeglio O; Cassoni P; Valente G; Schiffer D
    J Neurooncol; 2011 Nov; 105(2):345-57. PubMed ID: 21643842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.
    Sanson M; Marie Y; Paris S; Idbaih A; Laffaire J; Ducray F; El Hallani S; Boisselier B; Mokhtari K; Hoang-Xuan K; Delattre JY
    J Clin Oncol; 2009 Sep; 27(25):4150-4. PubMed ID: 19636000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Radiomics Analyses Based on Different Magnetic Resonance Imaging Sequences in Grading and Molecular Genomic Typing of Glioma.
    Huang WY; Wen LH; Wu G; Hu MZ; Zhang CC; Chen F; Zhao JN
    J Comput Assist Tomogr; 2021 Jan-Feb 01; 45(1):110-120. PubMed ID: 33475317
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.
    Thon N; Eigenbrod S; Kreth S; Lutz J; Tonn JC; Kretzschmar H; Peraud A; Kreth FW
    Cancer; 2012 Jan; 118(2):452-60. PubMed ID: 21717448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.
    Eigenbrod S; Trabold R; Brucker D; Erös C; Egensperger R; La Fougere C; Göbel W; Rühm A; Kretzschmar HA; Tonn JC; Herms J; Giese A; Kreth FW
    Acta Neurochir (Wien); 2014 Aug; 156(8):1427-40. PubMed ID: 24792966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MGMT Promoter Methylation and IDH1 Mutations Do Not Affect [
    Cimini A; Chiaravalloti A; Ricci M; Villani V; Vanni G; Schillaci O
    Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33066633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological Features and Prognosis of Indonesian Patients with Gliomas with IDH Mutation: Insights into Its Significance in a Southeast Asian Population.
    Malueka RG; Dwianingsih EK; Bayuangga HF; Panggabean AS; Argo IW; Donurizki AD; Shaleh S; Wicaksono AS; Dananjoyo K; Asmedi A; Hartanto RA
    Asian Pac J Cancer Prev; 2020 Aug; 21(8):2287-2295. PubMed ID: 32856857
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral Susceptibility Signals Reflect Biomarker Status in Gliomas.
    Kong LW; Chen J; Zhao H; Yao K; Fang SY; Wang Z; Wang YY; Li SW
    Sci Rep; 2019 Nov; 9(1):17080. PubMed ID: 31745161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.